Svb Leerink upgraded shares of SAGE Therapeutics (NASDAQ:SAGE) from an underperform rating to a market perform rating in a research report report published on Friday morning, BenzingaRatingsTable reports.
A number of other research firms also recently issued reports on SAGE. Goldman Sachs Group decreased their target price on SAGE Therapeutics from $227.00 to $263.00 in a research report on Thursday. SunTrust Banks cut SAGE Therapeutics from a buy rating to a hold rating and dropped their price target for the company from $210.00 to $70.00 in a research report on Thursday. Wedbush cut their price target on SAGE Therapeutics from $203.00 to $90.00 and set an outperform rating for the company in a research note on Thursday. Morgan Stanley reissued a buy rating and issued a $217.00 price objective on shares of SAGE Therapeutics in a report on Sunday, November 24th. Finally, Cowen reissued a buy rating and issued a $96.00 price objective on shares of SAGE Therapeutics in a report on Thursday. One analyst has rated the stock with a sell rating, six have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $128.81.
SAGE Therapeutics stock opened at $64.46 on Friday. The firm has a 50 day moving average price of $142.30 and a 200-day moving average price of $160.81. The company has a quick ratio of 12.67, a current ratio of 12.67 and a debt-to-equity ratio of 0.03. SAGE Therapeutics has a twelve month low of $56.50 and a twelve month high of $193.56. The company has a market capitalization of $3.34 billion, a P/E ratio of -7.98 and a beta of 2.52.
A number of hedge funds have recently bought and sold shares of the business. Amundi Pioneer Asset Management Inc. increased its holdings in shares of SAGE Therapeutics by 40.7% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 136,459 shares of the biopharmaceutical company’s stock worth $21,704,000 after purchasing an additional 39,447 shares during the period. Commonwealth Equity Services LLC boosted its stake in SAGE Therapeutics by 4.5% during the second quarter. Commonwealth Equity Services LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 77 shares during the period. Creative Planning grew its position in SAGE Therapeutics by 13.0% during the second quarter. Creative Planning now owns 2,563 shares of the biopharmaceutical company’s stock worth $469,000 after buying an additional 294 shares in the last quarter. Janney Capital Management LLC grew its position in SAGE Therapeutics by 18.2% during the second quarter. Janney Capital Management LLC now owns 4,387 shares of the biopharmaceutical company’s stock worth $803,000 after buying an additional 675 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its stake in SAGE Therapeutics by 5.0% in the 2nd quarter. Janney Montgomery Scott LLC now owns 4,557 shares of the biopharmaceutical company’s stock worth $834,000 after acquiring an additional 219 shares during the last quarter.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.